title: [Secondary prevention and conservative therapy of obliterative arteriosclerosis].
abstract: The author gives an overview of the main ways of medical therapy for patients with peripheral arterial obliterative disease. The importance of possible modification of the risk factors is emphasized especially beneficial effects of supervised walking-based exercise program. It is considered proven that the antiplatelet therapy and antilipidemic treatment reduce the risk of progressive atherosclerotic processes. The author summarizes the mechanisms and clinical effects of drugs influencing haemostation and haemorheology as well as vasodynamic agents. The results of clinical trials show a marked improvement of intermittent claudication by combination of preventive and therapeutic ways in majority of patients with peripheral arterial obliterative disease.
authors.affiliation: Fóvárosi Szent István Kórház, IV. Belgyógyászati Osztály, Budapest.
authors.forename: Anna
authors.initials: A
authors.lastname: Landi
mesh_terms: D001162:Arteriosclerosis Obliterans / Q000150:complications / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control / Q000628:therapy*; D000077407:Cilostazol; D002986:Clinical Trials as Topic; D011464:Epoprostenol / Q000627:therapeutic use; D015444:Exercise; D006401:Hematologic Agents / Q000627:therapeutic use*; D006438:Hemodilution; D018056:Hemorheology / Q000187:drug effects; D006801:Humans; D020138:Hyperhomocysteinemia / Q000150:complications; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D007383:Intermittent Claudication / Q000209:etiology / Q000517:prevention & control*; D009257:Nafronyl / Q000627:therapeutic use; D010431:Pentoxifylline / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011759:Pyrrolidines / Q000627:therapeutic use; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects; D013777:Tetrazoles / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use*; D016138:Walking
chemical_list: D006401:Hematologic Agents; D000960:Hypolipidemic Agents; D010975:Platelet Aggregation Inhibitors; D011759:Pyrrolidines; D013777:Tetrazoles; D014665:Vasodilator Agents; D009257:Nafronyl; D011464:Epoprostenol; D000077407:Cilostazol; D010431:Pentoxifylline; C010651:buflomedil